Abstract Search

ea0098c39 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Repeat peptide receptor radionuclide therapy in neuroendocrine neoplasms: a NET center of excellence experience

Grewal, MD Udhayvir Singh , Paschke, MD Alexander , Dillon, MD Joseph , Chandrasekharan, MD Chandrikha

Background: Lu177 DOTATATE Peptide Receptor Radionucleotide Therapy (PRRT) was FDA approved in the United States in 2018, however, the data for the safety and efficacy of repeat PRRT are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients.Methods: We used our single-center longitudinal IRB approved neuroendocrine tumor (NET) registry to identify patients who had been previously treated wi...

0 shares

ea0098c40 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Evaluation of long-term hepatic adverse events in patients receiving Peptide Receptor Radionuclide Therapy (PRRT) following BLAND embolization

Singh Grewal, MD Udhayvir , Paschke, MD Alexander , Dillon, MD Joseph , Chandrasekharan, MD Chandrikha

Background: Clinicians are concerned about increased hepatotoxicity in patients who received hepatic artery bland embolizations (TAE) and subsequent Peptide Receptor Radionuclide Therapy (PRRT). The body of literature describing the safety of PRRT following prior TAE is very limited. The purpose of this study is to evaluate the degree of long-term liver toxicity in patients who received PRRT in addition to previous hepatic embolizations for liver dominant disease.<p class=...

2 shares

ea0089t3 | Trials In Progress | NANETS2022

Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome

Chauhan, MD Aman , Shaheen, MD Shagufta , Usiskin, MD Keith , Odueyungbo, PhD Ade , Mui, BSc Cosina , Dillon, MD Joseph

Background: Neuroendocrine tumors (NETs) are classified as functional or non-functional based on the presence of characteristic symptoms, related to tumoral secretion of biologically active peptides or amines. Carcinoid Syndrome (CS) is the commonest functional NET syndrome, seen at diagnosis in 19% of patients. It is characterized in over 80% of cases by watery diarrhea (mainly due to serotonin hypersecretion) or cutaneous flushing. Somatostatin is a neuropeptide that inhibit...

0 shares

ea0089c32 | Clinical – Surgery/Applied Pathology | NANETS2022

Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Ziogas, MD, MPH Ioannis A. , T. Tasoudis, MD Panagiotis , C. Borbon, MD Luis , K. Sherman, MD, FACS Scott , J. Breheny, MS, PhD Patrick , Chandrasekharan, MBBS Chandrikha , S. Dillon, MD Joseph , M. Bellizzi, MD Andrew , R. Howe, MD, FACS James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare, aggressive tumors with poor prognosis. The WHO 2017 classification further subdivided G3 NENs into G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Current guidelines favor medical management in most of these patients, and the role of surgical management is not well-defined. We performed a systematic literature review and meta-analysis of surgical management vs ...

0 shares

ea0089c37 | Clinical – Surgery/Applied Pathology | NANETS2022

Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

C. Borbon, MD Luis , G. Tran, MD Catherine , K. Sherman, MD Scott , Hien Ear, PhD Po , Chandrasekharan, MD Chandrikha , M. Bellizzi, MD Andrew , S. Dillon, MD Joseph , M. O'Dorisio, MD Thomas , R. Howe, MD James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are aggressive tumors with poor survival outcomes for which medical management is usually recommended. This study sought to evaluate outcomes of surgically treated G3 GEP-NEN patients.Methods: A single-institutional prospective NEN database was reviewed. Patients with G3 GEP-NENs based on World Health Organization (WHO) 2019 definitions included well-differentiated neur...

0 shares

Endocrine Abstracts

Repeat peptide receptor radionuclide therapy in neuroendocrine neoplasms: a NET center of excellence experience

Evaluation of long-term hepatic adverse events in patients receiving Peptide Receptor Radionuclide Therapy (PRRT) following BLAND embolization

Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome

Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

BiosciAbstracts